Vancouver, BC, February 9, 2023--Acuitas Therapeutics announced that Dr. Thomas Madden, the company's President & CEO, has been named one of EY's 10 Canadian National Winners in their Entrepreneur of the Year program, in recognition of his commitment to innovation and entrepreneurial spirit.

Vancouver, BC, October 5, 2022--Acuitas Therapeutics announced that Dr. Thomas Madden, the company's President & CEO, has received BIOTECanada's 2022 Gold Leaf Award in the Game Changing Industry Leadership category.

Vancouver, BC, October 4, 2022--Bloom Burton & Co. announced Pieter Cullis, Co-Founder of Vancouver-based biotech company Acuitas Therapeutics, as the recipient of the 2022 Bloom Burton Award for making the greatest contribution to Canada's innovative health care industry in 2021.

Vancouver, BC, September 1, 2022--The founders of Acuitas Therapeutics, Drs. Pieter Cullis, Michael Hope and Thomas Madden, have been named as Governor General's Innovation Award recipients. This prestigious award is for their work in developing lipid nanoparticle (LNP) systems to deliver cancer drugs to tumours and to enable RNA- and DNA-based drugs to be used therapeutically.

Vancouver, BC, January 11, 2022--Pharma Giant Pfizer Inc. (NYSE: PFE) and Acuitas Therapeutics, a Vancouver-based company focused on developing lipid nanoparticle (LNP) delivery systems to enable messenger RNA (mRNA)-based therapeutics, announced they have entered into a Development and Option agreement under which Pfizer will have the option to license, on a non-exclusive basis, Acuitas' LNP technology for up to 10 targets for vaccine or therapeutic development.

Vancouver, BC, November 19, 2020--BioNTech and Pfizer have announced positive efficacy data from an interim analysis of their Phase 3 COVID-19 trial results. A Vancouver-based biotechnology company, Acuitas Therapeutics, plays a key role in the development of this urgently needed messenger RNA (mRNA) vaccine.

Vancouver, BC, July 23, 2020--Acuitas Therapeutics, a Vancouver-based biotechnology company that specializes in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles (LNP), says it is seeing its already substantial reputation as a global expert in this area go further.